Clinical benefits, echocardiographic and MRI assessment after pulmonary sequestration treatment
| Autor: | Francesco Borgia, Francesca Esposito, Felice Mongiello, Carmine Mollica, Silvia Montella, Luca Botta, Antonio Rapacciuolo, Francesca Santamaria, Bruno Trimarco, Gaetano Di Palma |
|---|---|
| Přispěvatelé: | Borgia, Francesco, Santamaria, Francesca, Mollica, Carmine, Mongiello, Felice, Esposito, Francesca, Palma, Gaetano, Botta, Luca, Montella, Silvia, Trimarco, Bruno, Rapacciuolo, Antonio |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Percutaneous Pediatric cardiology Septal Occluder Device medicine.medical_treatment 030204 cardiovascular system & hematology Revascularization Asymptomatic Ultrasonography Prenatal Pulmonary sequestration Embolization 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Internal medicine medicine Humans Bronchopulmonary Sequestration Respiratory system business.industry Infant medicine.disease Magnetic Resonance Imaging Treatment Outcome medicine.anatomical_structure Echocardiography Child Preschool Cardiology Female Radiology medicine.symptom Cardiology and Cardiovascular Medicine business Shunt (electrical) MRI Follow-Up Studies Artery |
| Zdroj: | International Journal of Cardiology. 240:165-171 |
| ISSN: | 0167-5273 |
| DOI: | 10.1016/j.ijcard.2017.04.102 |
| Popis: | Background This study aimed to explore systematically procedural results, clinical benefits with echocardiographic and chest-MRI assessment of pulmonary sequestration percutaneous treatment. Methods 13 consecutive infants and children with diagnosis of isolated pulmonary sequestration (PS) had percutaneous closure of the aberrant artery supplying pulmonary sequestration between 2010 and 2015. By protocol, echocardiographic and chest-MRI assessment was performed before and respectively at 6–12months and 1year with the aim to study the effects of embolization on heart volume overload and regression of pulmonary sequestration. Results Median age at diagnosis was 1year (95%CI 0–2.6); median age at treatment was 1.3years (95%CI1.01–2.85). In all pts the PS was confirmed by chest-MRI. Procedural success was 100%. After treatment, pts experiencing previously respiratory symptoms/infections remained asymptomatic at 2.9year follow-up. In pts with significant shunt due to PS, treatment resulted in amelioration in left or right cardiac chamber enlargement at 6 and 12month follow-up. At distance from PS closure (median 14months), chest-MRI confirmed the closure of the aberrant artery and PS regression in 12 patients. In one case, despite the acute procedural success and the supplying artery remained closed, MRI detected residual PS revascularization. Conclusions Percutaneous PS closure in infants and children is safe and provide regression in respiratory symptoms and heart chamber dilatation if significant shunt is present. MRI is able to define aberrant artery course and PS parenchima, and might represent a valid instrument to study residual PS parenchima during growth. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect